Condition

Refractory Plasma Cell Myeloma

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions25

Lead sponsors shown2

Clinical trials

2 shown

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01

TERMINATED

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionNCT02109224 · 2014-09-01

TERMINATED

Common interventions

AbemaciclibDRUG1AbirateroneDRUG1AfatinibDRUG1BevacizumabBIOLOGICAL1BicalutamideDRUG1Biospecimen CollectionPROCEDURE1BortezomibDRUG1CabazitaxelDRUG1CabozantinibDRUG1CapecitabineDRUG1CarboplatinDRUG1CelecoxibDRUG1CobimetinibDRUG1CopanlisibDRUG1DabrafenibDRUG1DacomitinibDRUG1DarolutamideDRUG1DasatinibDRUG1DoxorubicinDRUG1DurvalumabBIOLOGICAL1EnasidenibDRUG1EntrectinibDRUG1EnzalutamideDRUG1ErlotinibDRUG1EverolimusDRUG1

Leading sponsors

National Cancer Institute (NCI)1OHSU Knight Cancer Institute1

Trial status mix

TERMINATED2

Phase mix

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.